- Clinical Trials
Our diabetes gene therapy candidate, GPX-002, has the potential to treat Type 1 and Type 2 diabetes, which together currently affect approximately 34.2 million people in the U.S., or 10.5 percent of the population.
According to the International Diabetes Federation, in 2019 about 463 million people worldwide had diabetes, and 4.2 million deaths were attributed to diabetes. Diabetes patients have the continuous burden of checking and monitoring their blood glucose levels and injecting insulin on a daily basis. Without effective management of diabetes, patients are at risk of stroke, hyperglycemia, cardiovascular disease, diabetic ketoacidosis and extremity amputation. Both the number of cases and the prevalence of diabetes have been steadily increasing over the past few decades.